Literature DB >> 23105733

Unusually high serum CA19.9 in gastric carcinoma: A case report.

Vinita Thakur1, U Mukherjee.   

Abstract

We describe a case of poorly differentiated adenocarcinoma of stomach, which did not present typical symptoms of gastrointestinal malignancy on first visit. The patient, a 62 year old smoker presented with shortness of breathe and pain in right lumbar region with no history of fever. Bone scans revealed multiple hot spots in skull, sternum, lumbar vertebrae and both iliac crests. A series of tumor markers were ordered which include PSA, CEA, CA19.9, CA 72.4 and AFP. Serum PSA and AFP concentrations were within normal range. Serum CEA and CA 72.4 were raised significantly. Markedly elevated levels of serum CA19.9 were found (>45000 U/ml) in this patient. CT chest and bronchoscopic examination ruled out the possibility of cancer lung. Upper GI tract endoscopy was done to find out lesion in GI tract. An ulcerative lesion was found in lesser curvature of stomach. Histopathological examination of endoscopic biopsy revealed a poorly differentiated adenocarcinoma of stomach. An unusually high serum CA19.9 (>45000U/ml) in case of gastric carcinoma has not been reported earlier.

Entities:  

Keywords:  CA 19.9; CA72.4; CEA; Gastric Carcinoma; Pancreas

Year:  2008        PMID: 23105733      PMCID: PMC3453653          DOI: 10.1007/s12291-008-0025-3

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  10 in total

1.  Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.

Authors:  T Yamao; S Kai; A Kazami; K Koizumi; T Handa; N Takemoto; M Maruyama
Journal:  Jpn J Clin Oncol       Date:  1999-11       Impact factor: 3.019

2.  A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum.

Authors:  D W Moss; L G Whitby
Journal:  Clin Chim Acta       Date:  1975-05-15       Impact factor: 3.786

3.  The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA.

Authors:  N Duraker; A N Celik
Journal:  J Surg Oncol       Date:  2001-04       Impact factor: 3.454

4.  An endogastric capsule for measuring tumor markers in gastric juice: an evaluation of the safety and efficacy of a new diagnostic tool.

Authors:  P Muretto; F Graziano; M P Staccioli; I Barbanti; A Bartolucci; G Paolini; D Giordano; E Testa; A De Gaetano
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

5.  Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72).

Authors:  T L Klug; M A Sattler; D Colcher; J Schlom
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

6.  Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.

Authors:  M J Gaspar; I Arribas; M C Coca; M Díez-Alonso
Journal:  Tumour Biol       Date:  2001 Sep-Oct

7.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

8.  Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma.

Authors:  T Wobbes; C M Thomas; M F Segers; F M Nagengast
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

9.  Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients.

Authors:  C Dittrich; R Jakesz; L Havelec; R Lenzhofer; S Breyer; K Moser
Journal:  Cancer Detect Prev       Date:  1985

10.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.

Authors:  K Sakamoto; Y Haga; R Yoshimura; H Egami; Y Yokoyama; M Akagi
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.